Literature DB >> 21044429

Measuring methotrexate polyglutamates.

S Goodman1.   

Abstract

Methotrexate is the most commonly used drug in the treatment of rheumatoid arthritis, although 30-40% of patients fail to adequately respond. An accurate method for measuring methotrexate polyglutamates, the stable active metabolite of methotrexate, has recently been described. The objective of this review article is to determine if clinical use of this measurement would improve methotrexate efficacy, or decrease adverse reactions. Additionally the pharmacologic rationale for this test is discussed. Although methotrexate response improves at higher methotrexate polyglutamate levels, there is no absolute correlation of level with effect. Moreover, overlapping methotrexate polyglutamate levels between clinical responders and nonresponders limits the clinical utility of this measurement.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21044429

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  3 in total

Review 1.  [Treat to target and personalized medicine (precision medicine)].

Authors:  J Detert; G R Burmester
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

2.  Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis.

Authors:  L A Davis; B Polk; A Mann; R K Wolff; G S Kerr; A M Reimold; G W Cannon; T R Mikuls; L Caplan
Journal:  Clin Exp Rheumatol       Date:  2014-01-20       Impact factor: 4.473

3.  Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.

Authors:  Z Xia; J Lyu; N Hou; L Song; X Li; H Liu
Journal:  Z Rheumatol       Date:  2016-10       Impact factor: 1.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.